Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 17/20 | 0.62 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.58 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954242 | 0.92 | FFAR1 (0.54) | FFAR1FFAR4SLC22A12 | |
| SCHEMBL959881 | 0.91 | CYSLTR2 (0.58) | FFAR1FFAR4SLC22A12 | |
| SCHEMBL1634145 | 0.90 | CYSLTR2 (0.57) | FFAR1FFAR4SLC22A12 | |
| SCHEMBL1634802 | 0.90 | CYSLTR2 (0.57) | FFAR1FFAR4SLC22A12 | |
| SCHEMBL1634166 | 0.90 | CYSLTR2 (0.57) | FFAR1FFAR4SLC22A12 | |
| SCHEMBL957978 | 0.86 | SLC22A12 (0.68) | FFAR1SLC22A12 | |
| SCHEMBL1634208 | 0.85 | PPARA (0.54) | FFAR1FFAR4SLC22A12 | |
| SCHEMBL2772855 | 0.84 | FFAR1 (0.83) | FFAR1FFAR4 | |
| SCHEMBL17413808 | 0.83 | FFAR1 (0.82) | FFAR1FFAR4 | |
| SCHEMBL13618536 | 0.82 | SLC22A12 (0.50) | FFAR1SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | claimed |
| US-9115072-B2 | Compounds and method for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-08-25 | — | — | US | claimed |
| EP-1601251-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2014-11-12 | — | — | EP | claimed |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-03 | — | — | US | claimed |
| US-7932290-B2 | Method for the treatment of metabolic disorders | WELLSTAT BIOLOGICS CORPORATION (US) | 2011-04-26 | — | — | US | claimed |
| US-20110014176-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-01-20 | — | — | US | claimed |
| EP-2268141-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2011-01-05 | — | — | EP | claimed |
| EP-2266946-A2 | Compound For The Treatment Of Metabolic Disorders | Wellstat Therapeutics Corporation (US) | 2010-12-29 | — | — | EP | claimed |
| US-20100087541-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-04-08 | — | — | US | claimed |
| WO-2009151695-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-12-17 | — | — | WO | claimed |
| US-7615575-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-11-10 | — | — | US | claimed |
| US-7605181-B2 | Method for the treatment of metabolic disorders | Wellstat Therapeutics Orporation (US) | 2009-10-20 | — | — | US | claimed |
| US-20080015254-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-01-17 | — | — | US | claimed |
| EP-1601251-A4 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2007-03-28 | — | — | EP | claimed |
| US-20060247309-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2006-11-02 | — | — | US | claimed |
| EP-1601251-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2005-12-07 | — | — | EP | claimed |
| WO-2004073611-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-09-02 | — | — | WO | claimed |
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-1601251-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004073611-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087541-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | CPT1B, FABP1, CPT1A | FFAR1 5/4885FFAR4 13/4885SLC22A12 1447/4885 |
| US-20080015254-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | CPT1B, FABP1, CPT1A | FFAR1 5/4885FFAR4 13/4885SLC22A12 1447/4885 |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | RCC2, HAX1, SLC10A6 | FFAR1 5/4885FFAR4 186/4885SLC22A12 139/4885 |
| US-20060247309-A1 | Compounds for the treatment of metabolic disorders | CPT1B, CPT1A, FABP1 | FFAR1 6/4885FFAR4 19/4885SLC22A12 908/4885 |
| US-20110014176-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | UGP2, TAS2R46, PYCARD | FFAR1 513/4885FFAR4 1026/4885SLC22A12 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.